294 related articles for article (PubMed ID: 12787138)
1. Mcl-1 antisense therapy chemosensitizes human melanoma in a SCID mouse xenotransplantation model.
Thallinger C; Wolschek MF; Wacheck V; Maierhofer H; Günsberg P; Polterauer P; Pehamberger H; Monia BP; Selzer E; Wolff K; Jansen B
J Invest Dermatol; 2003 Jun; 120(6):1081-6. PubMed ID: 12787138
[TBL] [Abstract][Full Text] [Related]
2. Mcl-1 is a novel therapeutic target for human sarcoma: synergistic inhibition of human sarcoma xenotransplants by a combination of mcl-1 antisense oligonucleotides with low-dose cyclophosphamide.
Thallinger C; Wolschek MF; Maierhofer H; Skvara H; Pehamberger H; Monia BP; Jansen B; Wacheck V; Selzer E
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4185-91. PubMed ID: 15217956
[TBL] [Abstract][Full Text] [Related]
3. [At the front line of malignant melanoma, great maneuvers: to cut the road to Bcl2 and "attack with chemotherapy"].
Bénard J
Bull Cancer; 1998 Jun; 85(6):520-1. PubMed ID: 9752277
[No Abstract] [Full Text] [Related]
4. Activity of a novel bcl-2/bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic origins.
Gautschi O; Tschopp S; Olie RA; Leech SH; Simões-Wüst AP; Ziegler A; Baumann B; Odermatt B; Hall J; Stahel RA; Zangemeister-Wittke U
J Natl Cancer Inst; 2001 Mar; 93(6):463-71. PubMed ID: 11259472
[TBL] [Abstract][Full Text] [Related]
5. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group.
Bedikian AY; Millward M; Pehamberger H; Conry R; Gore M; Trefzer U; Pavlick AC; DeConti R; Hersh EM; Hersey P; Kirkwood JM; Haluska FG;
J Clin Oncol; 2006 Oct; 24(29):4738-45. PubMed ID: 16966688
[TBL] [Abstract][Full Text] [Related]
6. Apoptosis, Bcl-2 antisense, and cancer therapy.
Piro LD
Oncology (Williston Park); 2004 Nov; 18(13 Suppl 10):5-10. PubMed ID: 15651171
[TBL] [Abstract][Full Text] [Related]
7. bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice.
Jansen B; Schlagbauer-Wadl H; Brown BD; Bryan RN; van Elsas A; Müller M; Wolff K; Eichler HG; Pehamberger H
Nat Med; 1998 Feb; 4(2):232-4. PubMed ID: 9461199
[TBL] [Abstract][Full Text] [Related]
8. Chemosensitisation of malignant melanoma by BCL2 antisense therapy.
Jansen B; Wacheck V; Heere-Ress E; Schlagbauer-Wadl H; Hoeller C; Lucas T; Hoermann M; Hollenstein U; Wolff K; Pehamberger H
Lancet; 2000 Nov; 356(9243):1728-33. PubMed ID: 11095261
[TBL] [Abstract][Full Text] [Related]
9. Comparison of a treatment strategy combining CCI-779 plus DTIC versus DTIC monotreatment in human melanoma in SCID mice.
Thallinger C; Werzowa J; Poeppl W; Kovar FM; Pratscher B; Valent P; Quehenberger P; Joukhadar C
J Invest Dermatol; 2007 Oct; 127(10):2411-7. PubMed ID: 17508024
[TBL] [Abstract][Full Text] [Related]
10. Bcl-X(L) is a chemoresistance factor in human melanoma cells that can be inhibited by antisense therapy.
Heere-Ress E; Thallinger C; Lucas T; Schlagbauer-Wadl H; Wacheck V; Monia BP; Wolff K; Pehamberger H; Jansen B
Int J Cancer; 2002 May; 99(1):29-34. PubMed ID: 11948488
[TBL] [Abstract][Full Text] [Related]
11. Mcl-1 blocks radiation-induced apoptosis and inhibits clonogenic cell death.
Skvara H; Thallinger C; Wacheck V; Monia BP; Pehamberger H; Jansen B; Selzer E
Anticancer Res; 2005; 25(4):2697-703. PubMed ID: 16080514
[TBL] [Abstract][Full Text] [Related]
12. Bcl-2 antisense oligonucleotides (G3139) inhibit Merkel cell carcinoma growth in SCID mice.
Schlagbauer-Wadl H; Klosner G; Heere-Ress E; Waltering S; Moll I; Wolff K; Pehamberger H; Jansen B
J Invest Dermatol; 2000 Apr; 114(4):725-30. PubMed ID: 10733680
[TBL] [Abstract][Full Text] [Related]
13. Oblimersen in the treatment of metastatic melanoma.
Tarhini AA; Kirkwood JM
Future Oncol; 2007 Jun; 3(3):263-71. PubMed ID: 17547520
[TBL] [Abstract][Full Text] [Related]
14. Clusterin regulates drug-resistance in melanoma cells.
Hoeller C; Pratscher B; Thallinger C; Winter D; Fink D; Kovacic B; Sexl V; Wacheck V; Gleave ME; Pehamberger H; Jansen B
J Invest Dermatol; 2005 Jun; 124(6):1300-7. PubMed ID: 15955107
[TBL] [Abstract][Full Text] [Related]
15. Bcl-2 antisense oligonucleotides chemosensitize human gastric cancer in a SCID mouse xenotransplantation model.
Wacheck V; Heere-Ress E; Halaschek-Wiener J; Lucas T; Meyer H; Eichler HG; Jansen B
J Mol Med (Berl); 2001 Oct; 79(10):587-93. PubMed ID: 11692156
[TBL] [Abstract][Full Text] [Related]
16. Enhanced killing of melanoma cells by simultaneously targeting Mcl-1 and NOXA.
Qin JZ; Xin H; Sitailo LA; Denning MF; Nickoloff BJ
Cancer Res; 2006 Oct; 66(19):9636-45. PubMed ID: 17018621
[TBL] [Abstract][Full Text] [Related]
17. Mcl-1 overexpression in hepatocellular carcinoma: a potential target for antisense therapy.
Sieghart W; Losert D; Strommer S; Cejka D; Schmid K; Rasoul-Rockenschaub S; Bodingbauer M; Crevenna R; Monia BP; Peck-Radosavljevic M; Wacheck V
J Hepatol; 2006 Jan; 44(1):151-7. PubMed ID: 16289418
[TBL] [Abstract][Full Text] [Related]
18. Thalidomide enhances the anti-tumor activity of standard chemotherapy in a human melanoma xenotransplatation model.
Heere-Ress E; Boehm J; Thallinger C; Hoeller C; Wacheck V; Birner P; Wolff K; Pehamberger H; Jansen B
J Invest Dermatol; 2005 Aug; 125(2):201-6. PubMed ID: 16098027
[TBL] [Abstract][Full Text] [Related]
19. Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab.
Loomis R; Carbone R; Reiss M; Lacy J
Clin Cancer Res; 2003 May; 9(5):1931-9. PubMed ID: 12738752
[TBL] [Abstract][Full Text] [Related]
20. Antitumor effect of G3139 Bcl-2 antisense oligonucleotide is independent of its immune stimulation by CpG motifs in SCID mice.
Wacheck V; Krepler C; Strommer S; Heere-Ress E; Klem R; Pehamberger H; Eichler HG; Jansen B
Antisense Nucleic Acid Drug Dev; 2002 Dec; 12(6):359-67. PubMed ID: 12568310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
